Cross-sectorial Rehabilitation of Patients with Lung Cancer
Launched by CAMILLA BALLE · Nov 22, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to help patients with lung cancer, specifically a type called non-small cell lung cancer (NSCLC), get involved in rehabilitation programs that can improve their health and quality of life. In Denmark, many patients diagnosed with lung cancer are not participating in these important rehabilitation programs. The trial aims to see if setting up an "early contact conference" between the hospital and local communities can encourage more patients to join these programs. This conference will take place when patients are receiving their second treatment and will help everyone involved—like doctors and local health services—understand the patient's condition better.
To be eligible for this trial, participants should be receiving their first treatment for NSCLC and must be able to understand and communicate in Danish. If you join the trial, you can expect to have a conference call that connects your healthcare team and local support services, aimed at getting you the help you need as early as possible. This approach is easy to put into practice if it proves successful and is also cost-effective. The trial is currently recruiting participants, and it's open to all genders within the age range of 65 to 74 years.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with NSCLC
- • 1. line systemic treatment
- Exclusion Criteria:
- • cannot speak, understand, and/or read Danish
- • cognitive/psychologically unfit to give consent
About Camilla Balle
Camilla Balle is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on rigorous scientific methodology and ethical practices, Camilla Balle collaborates with leading healthcare professionals and institutions to facilitate the development of novel therapies and interventions. The organization prioritizes patient safety and data integrity, ensuring that each trial is designed to yield reliable results that contribute to the broader medical community. Through its commitment to excellence and transparency, Camilla Balle aims to drive meaningful progress in the healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herlev, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported